Confinement-induced drug-tolerance in mycobacteria mediated by an efflux mechanism

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Luthuli, Brilliant B ^a   Purdy, Georgiana E ^b   Balagaddé, Frederick K ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYGROMYCIN; ISONIAZID; OFLOXACIN; RIFAMPICIN; BAYSILON; CINNAMIC ACID DERIVATIVE; DIMETICONE; HYGROMYCIN B; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CELL DENSITY; CELL POPULATION; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG TOLERANCE; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; TUBERCULOSIS; UPREGULATION; ANALOGS AND DERIVATIVES; BACTERIAL LOAD; BIOLOGICAL MODEL; DIFFUSION; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; LAB ON A CHIP; MACROPHAGE; METABOLISM; MICROBIOLOGY; MICRODIALYSIS; TRANSPORT AT THE CELLULAR LEVEL;

ANTITUBERCULAR AGENTS; BACTERIAL LOAD; BIOLOGICAL TRANSPORT; CINNAMATES; DIFFUSION; DIMETHYLPOLYSILOXANES; DRUG TOLERANCE; EPIGENESIS, GENETIC; HUMANS; HYGROMYCIN B; ISONIAZID; LAB-ON-A-CHIP DEVICES; MACROPHAGES; MICRODIALYSIS; MODELS, BIOLOGICAL; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PHENOTYPE; RIFAMPIN;

EID: 84942927046     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136231     Document Type: Article

References (54)

1. Global tuberculosis report 2014. Geneva (Switzerland): World Health Organization, 2014 Contract No.: WHO/HTM/TB/2014.08.
2. Dye C, Lonnroth K, Jaramillo E, Williams BG, Raviglione M. Trends in tuberculosis incidence and their determinants in 134 countries. Bulletin of the World Health Organization. 2009; 87(9):683-91. Epub 2009/09/29. PMID: 19784448; PubMed Central PMCID: PMCPMC2739916.
3. Matteelli A, Roggi A, Carvalho AC. Extensively drug-resistant tuberculosis: epidemiology and management. Clinical epidemiology. 2014; 6:111. doi: 10.2147/CLEP.S35839 PMID: 24729727
4. Günther G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clinical Medicine. 2014; 14(3):279-85. doi: 10.7861/clinmedicine.14-3-279 PMID: 24889573
5. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. The Lancet. 2010; 375(9731):2100-9.
6. Gospodarevskaya E, Tulloch O, Bunga C, Ferdous S, Jonas A, Islam S, et al. Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens. The International Journal of Tuberculosis and Lung Disease. 2014; 18(7):810-7. doi: 10.5588/ijtld.13.0391 PMID: 24902557
7. Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2012; 16(6):724-32. Epub 2012/05/23. doi: 10.5588/ijtld.12.0083 PMID: 22613684; PubMed Central PMCID: PMCPMC3736084.
8. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. American journal of respiratory and critical care medicine. 2003; 167(10):1348-54. Epub 2003/01/10. doi: 10.1164/rccm.200210-1125OC PMID: 12519740.
9. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinburgh, Scotland). 2004; 84(1-2):29-44. Epub 2003/12/13. PMID: 14670344.
10. Hingley-Wilson SM, Sambandamurthy VK, Jacobs WR Jr. Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis. Nature immunology. 2003; 4(10):949-55. Epub 2003/09/30. doi: 10.1038/ni981 PMID: 14515128.
11. de Steenwinkel JE, de Knegt GJ, Marian T, van Belkum A, Verbrugh HA, Kremer K, et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. Journal of antimicrobial chemotherapy. 2010:dkq374.
12. Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS medicine. 2007; 4(3):e120. Epub 2007/03/29. doi: 10.1371/journal.pmed.0040120 PMID: 17388672; PubMed Central PMCID: PMCPMC1831743.
13. Aldridge BB, Fernandez-Suarez M, Heller D, Ambravaneswaran V, Irimia D, Toner M, et al. Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility. Science (New York, NY). 2012; 335(6064):100-4. Epub 2011/12/17. doi: 10.1126/science.1216166 PMID: 22174129; PubMed Central PMCID: PMCPMC3397429.
14. Wakamoto Y, Dhar N, Chait R, Schneider K, Signorino-Gelo F, Leibler S, et al. Dynamic persistence of antibiotic-stressed mycobacteria. Science (New York, NY). 2013; 339(6115):91-5. Epub 2013/01/05. doi: 10.1126/science.1229858 PMID: 23288538.
15. Golchin SA, Stratford J, Curry RJ, McFadden J. A microfluidic system for long-term time-lapse microscopy studies of mycobacteria. Tuberculosis (Edinburgh, Scotland). 2012; 92(6):489-96. Epub 2012/09/08. doi: 10.1016/j.tube.2012.06.006 PMID: 22954584.
16. Viveiros M, Martins M, Couto I, Rodrigues L, Machado D, Portugal I, et al. Molecular tools for rapid identification and novel effective therapy against MDRTB/XDRTB infections. Expert review of anti-infective therapy. 2010.
17. Schlesinger L. Lung Macrophages and Dendritic Cells in Health and Disease. 1997.
18. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, et al. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell. 2011; 145(1):39-53. Epub 2011/03/08. doi: 10.1016/j.cell.2011.02.022 PMID: 21376383; PubMed Central PMCID: PMCPMC3117281.
19. Hartkoorn RC, Chandler B, Owen A, Ward SA, Bertel Squire S, Back DJ, et al. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis (Edinburgh, Scotland). 2007; 87(3):248-55. Epub 2007/01/30. doi: 10.1016/j.tube.2006.12.001 PMID: 17258938.
20. Carnes EC, Lopez DM, Donegan NP, Cheung A, Gresham H, Timmins GS, et al. Confinement-induced quorum sensing of individual Staphylococcus aureus bacteria. Nature chemical biology. 2010; 6(1):41-5. Epub 2009/11/26. doi: 10.1038/nchembio.264 PMID: 19935660.
21. Horswill AR, Stoodley P, Stewart PS, Parsek MR. The effect of the chemical, biological, and physical environment on quorum sensing in structured microbial communities. Analytical and bioanalytical chemistry. 2007; 387(2):371-80. PMID: 17047948
22. Connell JL, Wessel AK, Parsek MR, Ellington AD, Whiteley M, Shear JB. Probing prokaryotic social behaviors with bacterial "lobster traps". MBio. 2010; 1(4):e00202-10. doi: 10.1128/mBio.00202-10 PMID: 21060734
23. Chaturvedi V, Dwivedi N, Tripathi RP, Sinha S. Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis. The Journal of general and applied microbiology. 2007; 53(6):333-7. Epub 2008/01/12. PMID: 18187888.
24. Krombach F, Munzing S, Allmeling AM, Gerlach JT, Behr J, Dorger M. Cell size of alveolar macrophages: an interspecies comparison. Environmental health perspectives. 1997; 105 Suppl 5:1261-3. Epub 1997/12/24. PMID: 9400735; PubMed Central PMCID: PMCPMC1470168.
25. Thorsen T, Maerkl SJ, Quake SR. Microfluidic large-scale integration. Science (New York, NY). 2002; 298(5593):580-4.
26. Mavrici D, Marakalala MJ, Holton JM, Prigozhin DM, Gee CL, Zhang YJ, et al. Mycobacterium tuberculosis FtsX extracellular domain activates the peptidoglycan hydrolase, RipC. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(22):8037-42. Epub 2014/05/21. doi: 10.1073/pnas.1321812111 PMID: 24843173; PubMed Central PMCID: PMCPMC4050617.
27. Purdy GE, Niederweis M, Russell DG. Decreased outer membrane permeability protects mycobacteria from killing by ubiquitin-derived peptides. Molecular microbiology. 2009; 73(5):844-57. doi: 10.1111/j.1365-2958.2009.06801.x PMID: 19682257
28. Vivino M. NIH Image Engineering (Scientific and image processing technical notes related to NIH Image) [cited 2015 July 11]. Available: http://rsb.info.nih.gov/nih-image/more-docs/Engineering/ImgEngr.html.
29. Li X, Tao J, Han J, Hu X, Chen Y, Deng H, et al. The gain of hydrogen peroxide resistance benefits growth fitness in mycobacteria under stress. Protein & cell. 2014; 5(3):182.
30. Barbassa L, Mamizuka EM, Carmona-Ribeiro AM. Supramolecular assemblies of rifampicin and cationic bilayers: preparation, characterization and micobactericidal activity. BMC biotechnology. 2011; 11 (1):40.
31. Waters CM, Bassler BL. Quorum sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev Biol. 2005; 21:319-46. PMID: 16212498
32. Miller MB, Bassler BL. Quorum sensing in bacteria. Annual Reviews in Microbiology. 2001; 55(1):165-99.
33. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. The EMBO journal. 2003; 22(15):3803-15. PMID: 12881415
34. Zhu J, Miller MB, Vance RE, Dziejman M, Bassler BL, Mekalanos JJ. Quorum-sensing regulators control virulence gene expression in Vibrio cholerae. Proceedings of the National Academy of Sciences. 2002; 99(5):3129-34.
35. Hammer BK, Bassler BL. Quorum sensing controls biofilm formation in Vibrio cholerae. Molecular microbiology. 2003; 50(1):101-4. PMID: 14507367
36. De Kievit TR, Gillis R, Marx S, Brown C, Iglewski BH. Quorum-sensing genes in Pseudomonas aeruginosa biofilms: their role and expression patterns. Applied and environmental microbiology. 2001; 67 (4):1865-73. PMID: 11282644
37. Kong K-F, Vuong C, Otto M. Staphylococcus quorum sensing in biofilm formation and infection. International Journal of Medical Microbiology. 2006; 296(2):133-9.
38. Lazazzera BA. Quorum sensing and starvation: signals for entry into stationary phase. Current opinion in microbiology. 2000; 3(2):177-82. PMID: 10744996
39. Ren D, Bedzyk LA, Rick WY, Thomas SM, Wood TK. Stationary-phase quorum-sensing signals affect autoinducer-2 and gene expression in Escherichia coli. Applied and environmental microbiology. 2004; 70(4):2038-43. PMID: 15066794
40. Redfield RJ. Is quorum sensing a side effect of diffusion sensing? Trends in microbiology. 2002; 10 (8):365-70. PMID: 12160634
41. Hense BA, Kuttler C, Muller J, Rothballer M, Hartmann A, Kreft JU. Does efficiency sensing unify diffusion and quorum sensing? Nature reviews Microbiology. 2007; 5(3):230-9. Epub 2007/02/17. doi: 10.1038/nrmicro1600 PMID: 17304251.
42. Boedicker JQ, Vincent ME, Ismagilov RF. Microfluidic confinement of single cells of bacteria in small volumes initiates high-density behavior of quorum sensing and growth and reveals its variability. Angewandte Chemie (International ed in English). 2009; 48(32):5908-11. Epub 2009/07/01. doi: 10.1002/anie.200901550 PMID: 19565587; PubMed Central PMCID: PMCPMC2748941.
43. De Rossi E, Ainsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS microbiology reviews. 2006; 30(1):36-52. Epub 2006/01/28. doi: 10.1111/j.1574-6976.2005.00002.x PMID: 16438679.
44. De Rossi E, Arrigo P, Bellinzoni M, Silva PA, Martin C, Ainsa JA, et al. The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Molecular medicine (Cambridge, Mass). 2002; 8(11):714-24. Epub 2003/01/10. PMID: 12520088; PubMed Central PMCID: PMCPmc2039957.
45. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Hernandez-Pando R, et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. American journal of respiratory and critical care medicine. 2011; 184(2):269-76. Epub 2011/04/23. doi: 10.1164/rccm.201011-1924OC PMID: 21512166; PubMed Central PMCID: PMCPmc3698754.
46. Louw GE, Warren RM, Gey van Pittius NC, McEvoy CR, Van Helden PD, Victor TC. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrobial agents and chemotherapy. 2009; 53 (8):3181-9. Epub 2009/05/20. doi: 10.1128/aac.01577-08 PMID: 19451293; PubMed Central PMCID: PMCPmc2715638.
47. Adams KN, Szumowski JD, Ramakrishnan L. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. Journal of Infectious Diseases. 2014; 210(3):456-66. doi: 10.1093/infdis/jiu095 PMID: 24532601
48. Balganesh M, Dinesh N, Sharma S, Kuruppath S, Nair AV, Sharma U. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrobial agents and chemotherapy. 2012; 56(5):2643-51. doi: 10.1128/AAC.06003-11 PMID: 22314527
49. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy. 2014; 58 (1):574-6. doi: 10.1128/AAC.01462-13 PMID: 24126586
50. Li X-Z, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs. 2009; 69(12):1555-623. doi: 10.2165/11317030-000000000-00000 PMID: 19678712
51. Pacheco SA, Hsu F-F, Powers KM, Purdy GE. MmpL11 protein transports mycolic acid-containing lipids to the mycobacterial cell wall and contributes to biofilm formation in Mycobacterium smegmatis. Journal of Biological Chemistry. 2013; 288(33):24213-22. doi: 10.1074/jbc.M113.473371 PMID: 23836904
52. Stratton CW. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerging infectious diseases. 2003; 9(1):10-6. Epub 2003/01/21. doi: 10.3201/eid0901.020172 PMID: 12533275; PubMed Central PMCID: PMCPMC2873758.
53. Heginbothom ML. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2001; 5(6):539-45. Epub 2001/06/21. PMID: 11409581.
54. Bottger EC. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2011; 17(8):1128-34. Epub 2011/06/03. doi: 10.1111/j.1469-0691.2011.03551.x PMID: 21631641.